Enabling the next generation of PRECISION GENOME EDITING
Hybridex Biosciences aims to enable the next generation of precision gene editing therapeutics through novel antisense technology. Our platform technology seeks to improve efficacy, safety, and versatility of both ex vivo and in vivo gene editing therapeutics.
CRISPR-PNA Therapeutics
Novel antisense platform technology designed to improve the accuracy of CRISPR-based systems to single nucleotide resolution
Superior Specificity
Improving CRISPR specificity can unlock new indications and de-risk current assets in development
Cas:PNA Tolerability
PNAs are not immunogenic and have no significant impact on cell viability.
Broad Delivery
PNAs are highly adaptable to various delivery technologies, making them versatile tools for diverse applications.
Universal Applicability
PNAs are a modular technology that can be easily incorporated across cas orthologs & new gene editing modalities
Let’s Work Together
We are actively seeking partners from academia, biotech or pharma to develop gene editing therapeutics across a host of different indications.